



NDA 21140/S-25

**SUPPLEMENT APPROVAL**

Johnson & Johnson Consumer, Inc.  
McNeil Consumer Healthcare Division  
Attention: Timothy Kline, Ph.D., RAC  
Senior Associate, Regulatory  
7050 Camp Hill Road  
Fort Washington, PA 19034-2210

Dear Dr. Kline:

Please refer to your Supplemental New Drug Application (sNDA) dated and received October 14, 2016, and amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Imodium<sup>®</sup> Multi-Symptom Relief (loperamide hydrochloride 2 mg, simethicone 125 mg) tablet.

This “Changes Being Effected” sNDA provides for the addition of the “Heart Alert” in accordance with the “Changes Being Effected” (CBE-0) Request Letter from the Agency dated August 12, 2016; and, revision of pediatric dosing as requested by the Agency on December 15, 2016.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**LABELING**

Submit final printed labeling as soon as they are available, but no more than 30 days after they are printed. The final printed labeling must be identical to the Imodium<sup>®</sup> Multi-Symptom Relief (loperamide hydrochloride 2 mg, simethicone 125 mg) tablet, 12-count carton (blister), 12-count carton (blister), 18-count carton (blister), 18-count carton (blister), 30-count carton (bottle), 30-count immediate container (bottle), 30-count carton (bottle), 30-count immediate container (bottle), 42-count carton (bottle), 42-count immediate container (bottle), 42-count carton (bottle), and 42-count immediate container (bottle) submitted on January 19, 2017, and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

The final printed labeling should be submitted electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 21140/S-025.**” Approval of this submission by FDA is not required before the labeling is used.

### **DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call CAPT Janice Adams-King, Safety Project Manager, at (301) 796-3713.

Sincerely,

*{See appended electronic signature page}*

Valerie Pratt, MD  
Deputy Director for Safety  
Division of Nonprescription Drug Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

### **ENCLOSURES:**

Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

VALERIE S PRATT  
04/12/2017